BMO Capital Markets began coverage on shares of Taysha Gene Therapies (NASDAQ:TSHA – Free Report) in a research report released on Thursday, Marketbeat.com reports. The brokerage issued an outperform rating and a $5.00 price objective on the stock.
TSHA has been the topic of a number of other research reports. Needham & Company LLC reaffirmed a buy rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a report on Monday, June 17th. Piper Sandler began coverage on Taysha Gene Therapies in a report on Tuesday, April 9th. They issued an overweight rating and a $9.00 target price on the stock. JMP Securities reaffirmed a market outperform rating and issued a $5.00 target price on shares of Taysha Gene Therapies in a report on Thursday, June 20th. Jefferies Financial Group reaffirmed a buy rating and issued a $8.00 target price (up previously from $2.00) on shares of Taysha Gene Therapies in a report on Tuesday, May 14th. Finally, Cantor Fitzgerald reaffirmed an overweight rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a report on Thursday, June 20th. Ten analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of Buy and an average target price of $6.80.
Read Our Latest Stock Analysis on TSHA
Taysha Gene Therapies Stock Performance
Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. The business had revenue of $3.41 million for the quarter, compared to analyst estimates of $3.70 million. Taysha Gene Therapies had a negative return on equity of 782.81% and a negative net margin of 833.60%. During the same quarter in the prior year, the firm posted ($0.28) EPS. As a group, equities research analysts expect that Taysha Gene Therapies will post -0.43 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Taysha Gene Therapies
Hedge funds and other institutional investors have recently modified their holdings of the stock. Howard Capital Management Inc. bought a new position in shares of Taysha Gene Therapies during the 4th quarter worth approximately $25,000. Victory Capital Management Inc. bought a new position in shares of Taysha Gene Therapies during the 4th quarter worth approximately $28,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Taysha Gene Therapies during the 4th quarter worth approximately $31,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Taysha Gene Therapies during the 4th quarter worth approximately $38,000. Finally, Cannon Global Investment Management LLC bought a new position in shares of Taysha Gene Therapies during the 1st quarter worth approximately $69,000. Institutional investors own 77.70% of the company’s stock.
Taysha Gene Therapies Company Profile
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.
See Also
- Five stocks we like better than Taysha Gene Therapies
- 5 discounted opportunities for dividend growth investors
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- MarketBeat Week in Review – 6/24 – 6/28
- Stock Analyst Ratings and Canadian Analyst Ratings
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.